+

WO1996011269B1 - Ligands tie-2, peocedes de production et utilisations de ces ligands - Google Patents

Ligands tie-2, peocedes de production et utilisations de ces ligands

Info

Publication number
WO1996011269B1
WO1996011269B1 PCT/US1995/012935 US9512935W WO9611269B1 WO 1996011269 B1 WO1996011269 B1 WO 1996011269B1 US 9512935 W US9512935 W US 9512935W WO 9611269 B1 WO9611269 B1 WO 9611269B1
Authority
WO
WIPO (PCT)
Prior art keywords
ligand
tie
nucleic acid
receptor
human
Prior art date
Application number
PCT/US1995/012935
Other languages
English (en)
Other versions
WO1996011269A9 (fr
WO1996011269A2 (fr
Filing date
Publication date
Priority claimed from US08/319,932 external-priority patent/US5643755A/en
Priority claimed from US08/348,492 external-priority patent/US5879672A/en
Priority claimed from US08/373,579 external-priority patent/US5650490A/en
Priority claimed from US08/418,595 external-priority patent/US5814464A/en
Priority to JP51267296A priority Critical patent/JP4054375B2/ja
Priority to ES95939501T priority patent/ES2154354T3/es
Priority to DK95939501T priority patent/DK0784683T3/da
Priority to AT95939501T priority patent/ATE199259T1/de
Priority to CA2202028A priority patent/CA2202028C/fr
Priority to MX9702530A priority patent/MX9702530A/es
Priority to EP95939501A priority patent/EP0784683B1/fr
Priority to CZ19971025A priority patent/CZ292453B6/cs
Priority to HU9800160A priority patent/HU221422B1/hu
Priority to NZ296638A priority patent/NZ296638A/xx
Priority to AU41295/96A priority patent/AU711111B2/en
Priority to DE69520149T priority patent/DE69520149T2/de
Application filed filed Critical
Priority to US08/817,318 priority patent/US6433143B1/en
Priority to PL95319586A priority patent/PL184642B1/pl
Priority to JP53053796A priority patent/JP4122056B2/ja
Priority to CA2216963A priority patent/CA2216963C/fr
Priority to DE69633121T priority patent/DE69633121T2/de
Priority to AT96910769T priority patent/ATE273384T1/de
Priority to AU53871/96A priority patent/AU715621B2/en
Priority to EP96910769A priority patent/EP0821728B1/fr
Priority to PCT/US1996/004806 priority patent/WO1996031598A1/fr
Publication of WO1996011269A2 publication Critical patent/WO1996011269A2/fr
Publication of WO1996011269A9 publication Critical patent/WO1996011269A9/fr
Publication of WO1996011269B1 publication Critical patent/WO1996011269B1/fr
Priority to NO19971557A priority patent/NO322643B1/no
Priority to FI971406A priority patent/FI120313B/fi
Priority to HK98105155A priority patent/HK1005944A1/xx
Priority to HK98109175A priority patent/HK1008230A1/xx
Priority to US09/442,717 priority patent/US6627415B1/en
Priority to GR20010400568T priority patent/GR3035717T3/el

Links

Abstract

Cette invention se rapporte à une molécule d'acide nucléique isolée codant un ligand TIE-2 humain. Cette invention se rapporte en outre à un corps récepteur qui fixe spécifiquement un ligand TIE-2 humain, et à un anticorps qui fixe spécifiquement un ligand TIE-2 humain, ainsi qu'à un antagoniste de ligand TIE-2 humain. Cette invention se rapporte également à des compositions thérapeutiques et à un procédé pour bloquer la croissance des vaisseaux sanguins, à un procédé pour promouvoir la néovascularisation, à un procédé pour promouvoir la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, à un procédé pour bloquer la croissance ou la différenciation d'une cellule exprimant le récepteur de TIE-2, ainsi qu'à un procédé pour atténuer ou empêcher la croissance de tumeurs chez l'homme.
PCT/US1995/012935 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands WO1996011269A2 (fr)

Priority Applications (27)

Application Number Priority Date Filing Date Title
PL95319586A PL184642B1 (pl) 1994-10-07 1995-10-06 Izolowana czasteczka kwasu nukleinowego kodujaca ligand TIE-2, wektor zawierajacy izolowana czasteczke kwasu nukleinowego, izolowany i oczyszczony ligand TIE-2, uklad gospodarz-wektor, sposób wytwarzania izolowanego i oczyszczonego ligandu TIE-2, przeciwcialo, cialo ligandu, koniugat, kompozycja farmaceutyczna, zastosowanie przeciwciala, zastosowanie izolowanego i oczyszczonego ligandu, sposób in vitro podtrzymywania w hodowli ekspresji receptora TIE-2, sposób identyfikacji antagonisty receptora TIE-2, cialo receptora, izolowana czasteczka kwasu nukleinowego kodujaca cialo receptora, wektor zawierajacy izolowana czasteczke kwasu nukleinowego kodujaca cialo receptora, kompozycja farmaceutyczna zawierajaca cialo receptora PL
US08/817,318 US6433143B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands
DE69520149T DE69520149T2 (de) 1994-10-07 1995-10-06 Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
CA2202028A CA2202028C (fr) 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands
CZ19971025A CZ292453B6 (cs) 1994-10-07 1995-10-06 Izolovaná molekula nukleové kyseliny kódující TIE-2 ligand a její použití
DK95939501T DK0784683T3 (da) 1994-10-07 1995-10-06 TIE-2-ligander, fremgangsmåder til dannelse af disse og anvendelser deraf
AT95939501T ATE199259T1 (de) 1994-10-07 1995-10-06 Tie-2 ligande, verfahren zu ihrer herstellung, und ihre anwendungen
JP51267296A JP4054375B2 (ja) 1994-10-07 1995-10-06 Ｔｉｅ−２リガンド、その作製方法および使用方法
MX9702530A MX9702530A (es) 1994-10-07 1995-10-06 Ligandos tie-2, metodos de preparacion y usos de los mismos.
EP95939501A EP0784683B1 (fr) 1994-10-07 1995-10-06 Ligands tie-2, procedes de production et utilisations de ces ligands
ES95939501T ES2154354T3 (es) 1994-10-07 1995-10-06 Ligandos tie-2, metodos para obtenerlos y sus usos.
HU9800160A HU221422B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands, recombinant methods of making and uses thereof
NZ296638A NZ296638A (en) 1994-10-07 1995-10-06 Ligands which bind to tie-2 (tyrosine kinase with ig and egf homology domains) receptors
AU41295/96A AU711111B2 (en) 1994-10-07 1995-10-06 Tie-2 ligands, methods of making and uses thereof
DE69633121T DE69633121T2 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung
JP53053796A JP4122056B2 (ja) 1995-04-06 1996-04-05 Ｔｉｅ−２リガンド、その作製方法および使用方法
AU53871/96A AU715621B2 (en) 1995-04-06 1996-04-05 TIE-2 ligands, methods of making and uses thereof
EP96910769A EP0821728B1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
PCT/US1996/004806 WO1996031598A1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
AT96910769T ATE273384T1 (de) 1995-04-06 1996-04-05 Tie-2 liganden, herstellungsverfahren und verwendung
CA2216963A CA2216963C (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
FI971406A FI120313B (fi) 1994-10-07 1997-04-04 TIE-2-ligandit, niiden valmistusmenetelmät ja käytöt
NO19971557A NO322643B1 (no) 1994-10-07 1997-04-04 Isolert nukleinsyremolekyl som koder for TIE-2-ligand, TIE-2-ligand, fremgangsmate ved fremstilling og anvendelse derav, samt antistoff mot TIE-2-liganden.
HK98105155A HK1005944A1 (en) 1994-10-07 1998-06-10 Tie-2 ligands, methods of making and uses thereof
HK98109175A HK1008230A1 (en) 1995-04-06 1998-07-15 Tie-2 ligands, methods of making and uses thereof.
US09/442,717 US6627415B1 (en) 1995-04-06 1999-11-18 TIE-2 ligands, methods of making and uses thereof
GR20010400568T GR3035717T3 (en) 1994-10-07 2001-04-06 Tie-2 ligands, methods of making and uses thereof

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
US08/319,932 US5643755A (en) 1994-10-07 1994-10-07 Nucleic acid encoding tie-2 ligand
US08/319,932 1994-10-07
US08/330,261 US5521073A (en) 1994-10-07 1994-10-27 TIE-2 ligand, and method of making
US08/330,261 1994-10-27
US08/348,492 1994-12-02
US08/348,492 US5879672A (en) 1994-10-07 1994-12-02 Tie-2 ligand 1
US35350394A 1994-12-09 1994-12-09
US08/353,503 1994-12-09
US08/373,579 US5650490A (en) 1994-10-07 1995-01-17 Tie-2 ligand 2
US08/373,579 1995-01-17
US08/418,595 1995-04-06
US08/418,595 US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US08/418,595 Continuation US5814464A (en) 1994-10-07 1995-04-06 Nucleic acids encoding TIE-2 ligand-2

Related Child Applications (5)

Application Number Title Priority Date Filing Date
US08/817,318 A-371-Of-International US6433143B1 (en) 1994-10-07 1995-10-06 Tie-2 ligands
PCT/US1996/004806 Continuation WO1996031598A1 (fr) 1995-04-06 1996-04-05 Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
US10/179,744 Division US20020173627A1 (en) 1999-09-16 2002-06-24 TIE-2 ligands, methods of making and uses thereof
US10/179,820 Division US20030166858A1 (en) 1999-09-16 2002-06-24 TIE-2 ligands, methods of making and uses thereof
US10/179,615 Division US7063840B2 (en) 1994-10-07 2002-06-24 TIE-2 ligands, methods of making and uses thereof

Publications (3)

Publication Number Publication Date
WO1996011269A2 WO1996011269A2 (fr) 1996-04-18
WO1996011269A9 WO1996011269A9 (fr) 1996-06-06
WO1996011269B1 true WO1996011269B1 (fr) 1996-08-22

Family

ID=27559710

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/012935 WO1996011269A2 (fr) 1994-10-07 1995-10-06 Ligands tie-2, peocedes de production et utilisations de ces ligands

Country Status (23)

Country Link
US (4) US5814464A (fr)
EP (1) EP0784683B1 (fr)
JP (1) JP4054375B2 (fr)
CN (1) CN1230536C (fr)
AT (1) ATE199259T1 (fr)
AU (1) AU711111B2 (fr)
CA (1) CA2202028C (fr)
CZ (1) CZ292453B6 (fr)
DE (1) DE69520149T2 (fr)
DK (1) DK0784683T3 (fr)
ES (1) ES2154354T3 (fr)
FI (1) FI120313B (fr)
GR (1) GR3035717T3 (fr)
HK (1) HK1005944A1 (fr)
HU (1) HU221422B1 (fr)
IL (4) IL115517A (fr)
MX (1) MX9702530A (fr)
NO (1) NO322643B1 (fr)
NZ (1) NZ296638A (fr)
PL (1) PL184642B1 (fr)
PT (1) PT784683E (fr)
WO (1) WO1996011269A2 (fr)
ZA (1) ZA958444B (fr)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5681714A (en) * 1992-07-30 1997-10-28 Mount Sinai Hospital Corporation Nucleic acid encoding tek receptor tyrosine kinase
US6221839B1 (en) 1994-11-14 2001-04-24 Helsinki University Licensing Ltd. Oy FIt4 ligand and methods of use
US6818220B1 (en) 1994-11-14 2004-11-16 Licentia Ltd. Vascular endothelial growth factor C (VEGF-C) protein and gene mutants thereof, and uses thereof
US6245530B1 (en) 1995-08-01 2001-06-12 Ludwig Institute For Cancer Research Receptor ligand
US6645933B1 (en) 1995-08-01 2003-11-11 Helsinki University Licensing Ltd. Oy Receptor ligand VEGF-C
US6130071A (en) * 1997-02-05 2000-10-10 Helsinki University Licensing, Ltd. Vascular endothelial growth factor C (VEGF-C) ΔCys156 protein and gene, and uses thereof
US6403088B1 (en) 1995-08-01 2002-06-11 Helsinki University Licensing, Ltd. Antibodies reactive with VEGF-C, a ligand for the Flt4 receptor tyrosine kinase (VEGFR-3)
WO1996031598A1 (fr) 1995-04-06 1996-10-10 Regeneron Pharmaceuticals, Inc. Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
AU755337B2 (en) * 1995-04-06 2002-12-12 Regeneron Pharmaceuticals, Inc. New uses of tie-2 ligands
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7727761B2 (en) 1995-08-01 2010-06-01 Vegenics Limited Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
ES2341864T3 (es) 1995-09-29 2010-06-29 Universita Degli Studi Di Siena Genes regulados y usos de los mismos.
US7063965B2 (en) * 1996-04-05 2006-06-20 Regeneron Pharmaceuticals, Inc. Nucleic acid encoding TIE-2 ligand
DE19623850A1 (de) * 1996-06-14 1997-12-18 Wacker Chemie Gmbh Homogenisierung von Dispersionen
ES2194203T3 (es) * 1996-06-19 2003-11-16 Regeneron Pharma Ligando del receptor tie-2 (ligando-4 de tie) y su uso.
US6846914B2 (en) 1996-06-19 2005-01-25 Regeneron Pharmaceuticals, Inc. Tie-2 ligand-3
US5851797A (en) * 1996-06-19 1998-12-22 Regeneron Pharmaceuticals, Inc. Tie ligand-3, methods of making and uses thereof
US6265564B1 (en) * 1996-08-02 2001-07-24 Regeneron Pharmaceuticals, Inc. Expressed ligand-vascular intercellular signalling molecule
US6235713B1 (en) 1996-08-23 2001-05-22 Ludwig Institute For Cancer Research Vascular endothelial growth factor-D (VEGF-D) polypeptides
US7125714B2 (en) 1997-02-05 2006-10-24 Licentia Ltd. Progenitor cell materials and methods
US6350450B1 (en) 1997-09-19 2002-02-26 Genentech, Inc. TIE ligand homologue antibody
US5972338A (en) 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
US6057435A (en) 1997-09-19 2000-05-02 Genentech, Inc. Tie ligand homologues
US6348350B1 (en) 1997-09-19 2002-02-19 Genentech, Inc. Ligand homologues
US6030831A (en) * 1997-09-19 2000-02-29 Genetech, Inc. Tie ligand homologues
AU1931599A (en) * 1997-12-19 1999-07-12 Zymogenetics Inc. Angiopoietin homolog, dna encoding it, and method of making it
IL136830A0 (en) * 1997-12-19 2001-06-14 Regeneron Pharma Receptor tyrosine kinase, ar-1
WO1999040193A1 (fr) * 1998-02-04 1999-08-12 Zymogenetics, Inc. Zapo3 homologue d'angiopoietine, adn le codant et sa methode de production
IL138216A0 (en) * 1998-03-02 2001-10-31 Millennium Pharm Inc Novel fdrg protein and nucleic acid molecules and uses therefor
US6479626B1 (en) 1998-03-02 2002-11-12 Massachusetts Institute Of Technology Poly zinc finger proteins with improved linkers
US7488590B2 (en) * 1998-10-23 2009-02-10 Amgen Inc. Modified peptides as therapeutic agents
EP2151454B1 (fr) 1998-11-10 2012-05-02 Ludwig Institute For Cancer Research Facteur de croissance D dérivés de plaquettes tronquée, l'ADN codant pour celui-ci et ses utilisations
NZ512326A (en) 1998-12-23 2003-11-28 Regeneron Pharma Fusion proteins containing at least two receptor binding domains and a multimer-forming component
EP1157111A1 (fr) * 1999-03-02 2001-11-28 Regeneron Pharmaceuticals, Inc. Proteine associee a l'angiopoietine et acides nucleiques correspondants
US6455035B1 (en) 1999-03-26 2002-09-24 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
US6703020B1 (en) 1999-04-28 2004-03-09 Board Of Regents, The University Of Texas System Antibody conjugate methods for selectively inhibiting VEGF
US6524583B1 (en) 1999-04-28 2003-02-25 Board Of Regents, The University Of Texas System Antibody methods for selectively inhibiting VEGF
US6521424B2 (en) 1999-06-07 2003-02-18 Immunex Corporation Recombinant expression of Tek antagonists
NZ516258A (en) * 1999-06-07 2004-02-27 Immunex Corp Tek antagonists
EP1956030B1 (fr) 1999-06-15 2009-11-11 Genentech, Inc. Polypeptides sécrétés et transmembranaires, et acides nucléiques les codant
US6689035B1 (en) 2000-04-11 2004-02-10 Gerber Scientific Products, Inc. Method and apparatus for designing and creating a package
CA2431308C (fr) 2000-12-07 2010-04-13 Sangamo Biosciences, Inc. Regulation de l'angiogenese au moyen de proteines a doigts de zinc
US7067317B2 (en) 2000-12-07 2006-06-27 Sangamo Biosciences, Inc. Regulation of angiogenesis with zinc finger proteins
US7658924B2 (en) * 2001-10-11 2010-02-09 Amgen Inc. Angiopoietin-2 specific binding agents
US7138370B2 (en) 2001-10-11 2006-11-21 Amgen Inc. Specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
AU2006228095B2 (en) * 2001-10-11 2010-11-04 Amgen Inc. Angiopoietin-2 specific binding agents
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US20050123925A1 (en) 2002-11-15 2005-06-09 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2002335085A1 (en) 2001-10-25 2003-05-06 Regeneron Pharmaceuticals, Inc. Angiopoietins and methods of use thereof
JP4242590B2 (ja) * 2002-01-11 2009-03-25 俊一 塩澤 慢性関節リウマチの疾患感受性遺伝子、及びその利用
US7427594B1 (en) * 2002-02-26 2008-09-23 The Trustees Of The University Of Pennsylvania Methods and pharmaceuticals compositions for treating coronary artery disease, ischemia,and vascular disease using angiopoietins
US7081443B2 (en) 2002-05-21 2006-07-25 Korea Advanced Institutes Of Science And Technology (Kaist) Chimeric comp-ang1 molecule
US20040115640A1 (en) * 2002-12-11 2004-06-17 Isis Pharmaceuticals Inc. Modulation of angiopoietin-2 expression
EP1545588A4 (fr) 2002-07-23 2007-12-05 Ludwig Inst Cancer Res Procedes et compositions pour l'activation ou l'inhibition du facteur de croissance endothelial vasculaire d et du facteur de croissance endothelial vasculaire c
AU2003297282A1 (en) 2002-11-14 2004-06-15 Cornell Research Foundation, Inc. Protection of cardiac myocardium
TWI395756B (zh) 2003-07-18 2013-05-11 Amgen Inc 對肝細胞生長因子具專一性之結合劑
CN1323723C (zh) * 2003-12-26 2007-07-04 上海新世界基因技术开发有限公司 Tie2受体介导的靶向性肿瘤基因治疗的基因转移系统
US8298532B2 (en) 2004-01-16 2012-10-30 Regeneron Pharmaceuticals, Inc. Fusion polypeptides capable of activating receptors
WO2005087177A2 (fr) 2004-03-05 2005-09-22 Ludwig Institute For Cancer Research Anticorps chimeriques anti-vegf-d et anticorps humanises anti-vegf-d et leurs procedes d'utilisation
JP4947717B2 (ja) * 2004-07-20 2012-06-06 ジェネンテック， インコーポレイテッド アンジオポエチン様４タンパク質のインヒビター、組み合わせ、およびそれらの使用
US8604185B2 (en) 2004-07-20 2013-12-10 Genentech, Inc. Inhibitors of angiopoietin-like 4 protein, combinations, and their use
EP2284194A1 (fr) 2004-12-21 2011-02-16 AstraZeneca AB Anticorps dirigés contre l'Angiopoiétine 2 et leurs utilisations
MX2007008326A (es) * 2005-01-07 2008-01-16 Univ Emory Antagonistas de cxcr4 para el tratamiento de una infeccion por vih.
JP4657757B2 (ja) * 2005-02-23 2011-03-23 株式会社膠原病研究所 肺高血圧症発症関連遺伝子を用いた肺高血圧症の診断および治療
JP2006325528A (ja) * 2005-05-27 2006-12-07 Institute For Rheumatic Diseases Co Ltd 糖尿病性網膜症の診断および予防
JP4657857B2 (ja) * 2005-08-25 2011-03-23 株式会社膠原病研究所 メタボリックシンドロームの診断および予防
WO2007068895A1 (fr) 2005-12-15 2007-06-21 Astrazeneca Ab Combinaison d'un antagoniste de l'angiopoietine 2 et d'un antagoniste du vegf-a et/ou du kdr et/ou du fltl pour le traitement du cancer
AR059066A1 (es) * 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
MX2008013990A (es) 2006-05-09 2009-01-29 Pfizer Prod Inc Derivados de cicloalquilamino acidos.
SI2188313T1 (en) 2007-08-21 2018-04-30 Amgen, Inc. HUMAN C-FMS ANTIGEN TRANSFER PROTEIN
US8227577B2 (en) * 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
US9266967B2 (en) 2007-12-21 2016-02-23 Hoffmann-La Roche, Inc. Bivalent, bispecific antibodies
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
GEP20156390B (en) 2008-01-03 2015-11-10 Scripps Research Inst Antibody targeting through a modular recognition domain
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
EP2247305A4 (fr) 2008-01-28 2012-11-14 Medimmune Ltd Anticorps stabilisés contre l'angiopoïétine-2 et leurs utilisations
JO2913B1 (en) 2008-02-20 2015-09-15 امجين إنك, Antibodies directed towards angiopoietin-1 and angiopoietin-2 proteins and their uses
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
US8268314B2 (en) 2008-10-08 2012-09-18 Hoffmann-La Roche Inc. Bispecific anti-VEGF/anti-ANG-2 antibodies
US8133979B2 (en) * 2008-12-16 2012-03-13 Hoffmann-La Roche Inc. Antibodies against human angiopoietin 2
CA2756244A1 (fr) * 2009-04-02 2010-10-07 Roche Glycart Ag Anticorps multispecifiques renfermant des anticorps de longueur entiere et des fragments fab a chaine unique
US20100256340A1 (en) 2009-04-07 2010-10-07 Ulrich Brinkmann Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
US8980268B2 (en) 2009-07-29 2015-03-17 Regeneron Pharamceuticals, Inc. Methods for treating cancer by administering an anti-Ang-2 antibody
US20120189635A1 (en) 2009-07-29 2012-07-26 Regeneron Pharmaceuticals, Inc. Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2)
JO3182B1 (ar) 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
WO2011038139A1 (fr) 2009-09-23 2011-03-31 Amgen Inc. Traitement du cancer de l'ovaire au moyen d'un agent de liaison spécifique de l'angiopoïétine-2 humaine en association avec un taxane
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
AR080794A1 (es) * 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
US20120100166A1 (en) 2010-07-15 2012-04-26 Zyngenia, Inc. Ang-2 Binding Complexes and Uses Thereof
BR112013001847A2 (pt) 2010-08-24 2016-05-31 Hoffmann La Roche anticorpo biespecífico, método de preparação do anticorpo biespecífico, do anticorpo biespecífico trivalente, métodos e composição farmacêutica
WO2012085111A1 (fr) 2010-12-23 2012-06-28 F. Hoffmann-La Roche Ag Complexe polypeptide-polynucléotide et son utilisation dans l'administration d'une fraction effectrice ciblée
CA2824824A1 (fr) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Proteines monovalentes de liaison a l'antigene
KR101638224B1 (ko) 2011-02-28 2016-07-08 에프. 호프만-라 로슈 아게 항원 결합 단백질
ES2704038T3 (es) 2011-05-24 2019-03-13 Zyngenia Inc Complejos multiespecíficos multivalentes y monovalentes y sus usos
AU2012275346B2 (en) 2011-06-29 2016-03-17 Amgen Inc. Predictive biomarker of survival in the treatment of renal cell carcinoma
JP6113756B2 (ja) 2012-01-23 2017-04-12 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． 抗ａｎｇ２抗体を含有する安定化製剤
JP6486686B2 (ja) 2012-02-10 2019-03-20 ジェネンテック， インコーポレイテッド 単鎖抗体及び他のヘテロ多量体
WO2013134516A1 (fr) 2012-03-08 2013-09-12 Medimmune, Llc Procédés de traitement par des anticorps anti-angiopoïétine-2
AR090263A1 (es) 2012-03-08 2014-10-29 Hoffmann La Roche Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
LT2831111T (lt) 2012-03-30 2019-05-10 Boehringer Ingelheim International Gmbh Ang2 surišančios molekulės
RU2639287C2 (ru) 2012-06-27 2017-12-20 Ф. Хоффманн-Ля Рош Аг Способ отбора и получения высокоселективных и мультиспецифичных нацеливающих групп с заданными свойствами, включающих по меньшей мере две различные связывающие группировки, и их применения
CA2871882A1 (fr) 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag Methode de fabrication de conjugues d'anticorps a region fc comprenant au moins une entite de liaison qui se lie specifiquement a une cible et leurs utilisations
EP3495387B1 (fr) 2012-07-13 2021-09-01 Roche Glycart AG Anticorps bispécifiques anti-vegf/anti-ang-2 et leur utilisation dans le traitement des maladies vasculaires oculaires
WO2014108854A1 (fr) 2013-01-09 2014-07-17 Fusimab Ltd. Anticorps anti-hgf et anti-ang2 monospécifiques, et anticorps anti-hgf/anti-ang2 bispécifiques
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
RU2016115866A (ru) 2013-10-11 2017-11-16 Ф. Хоффманн-Ля Рош Аг Мультиспецифические антитела с обменянными доменами и одинаковыми вариабельными доменами легкой цепи
BR112017005730B1 (pt) 2014-09-26 2023-12-12 Somalogic Operating Co., Inc Método para triagem de um indivíduo quanto ao risco de um evento cardiovascular ou para predizer a probabilidade que um indivíduo tenha tal evento
EP3207059A1 (fr) 2014-10-17 2017-08-23 Amgen Inc. Anticorps dirigés contre l'angiopoïétine 1 et l'angiopoïétine 2 pour thérapies oculaires
ES2764111T3 (es) 2014-12-03 2020-06-02 Hoffmann La Roche Anticuerpos multiespecíficos
JP6885870B2 (ja) 2015-03-04 2021-06-16 メゾブラスト・インターナショナル・エスアーエールエル 間葉系幹細胞の細胞培養法
WO2016209972A1 (fr) 2015-06-26 2016-12-29 Amgen Inc. Biomarqueur de survie dans le traitement d'un carcinome à cellules rénales avec un inhibiteur de vegfr et un inhibiteur d'ang2
HUE060148T2 (hu) 2015-12-16 2023-02-28 Regeneron Pharma Fehérje mikroszemcsékbõl álló készítmények és gyártási módszereik
CN109863171B (zh) 2016-08-23 2023-08-04 免疫医疗有限公司 抗vegf-a和抗ang2抗体及其用途
KR102716846B1 (ko) * 2017-01-30 2024-10-15 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
JP2020536967A (ja) 2017-10-12 2020-12-17 イミュノウェイク インコーポレイテッド Ｖｅｇｆｒ−抗体軽鎖融合タンパク質

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1995013387A1 (fr) * 1993-11-12 1995-05-18 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Nouvelle tyrosine-kinase receptrice appelee tie-2
US5879672A (en) * 1994-10-07 1999-03-09 Regeneron Pharmaceuticals, Inc. Tie-2 ligand 1
ATE230614T1 (de) * 1998-07-13 2003-01-15 Univ Texas Krebsbehandlung mit aminophospholipide bindenden, therapeutischen konjugaten

Similar Documents

Publication Publication Date Title
WO1996011269B1 (fr) Ligands tie-2, peocedes de production et utilisations de ces ligands
CA2202028A1 (fr) Ligands tie-2, peocedes de production et utilisations de ces ligands
CA2216963A1 (fr) Ligands tie-2, procedes d'obtention de ces ligands et leurs utilisations
RU97107471A (ru) Tie-2 лиганды, способы их получения и применения
JP3600617B2 (ja) ヒト上皮細胞成長因子レセプターに特異的なモノクローナル抗体及びそれを用いた治療剤
US6399068B1 (en) Method of treatment with a non-antigenic toxin-conjugate and fusion protein of internalizing receptor system
JP3589459B2 (ja) 生物応答調節物質の新規な抗体運送システム
AU618722B2 (en) Recombinant pseudomanas exotoxin: construction of an active immunotoxin with low side effects
DE69129421T2 (de) Interleukin 2 enthaltende rekombinante Immunkonjugate für die Therapie
AU631545B2 (en) Il-2 receptor-specific chimeric antibodies
EP3444277A1 (fr) Nanocorps anti-pd-l1, séquence de codage et utilisation associées
JP3541296B2 (ja) 腫瘍血管内皮細胞に特異的に結合するモノクローナル抗体とその利用方法
RU2183215C2 (ru) Конъюгат для стимулирования иммунной реакции против клетки-мишени, способ лечения злокачественных опухолей у млекопитающего
AU6084694A (en) Methods of delivering agents to target cells
Ross et al. Increased Toxicity of Diphtheria Toxin for Human Lymphoblastoid Cells following Covalent Linkage to Anti‐(human lymphocyte) Globulin or Its F (ab′) 2 Fragment
CA2097060A1 (fr) Anticorps bifonctionnels et leur methode de preparation
WO1994009149A1 (fr) Anticorps monoclonal
DE69934903T2 (de) Mitogene regulatoren
JPH08501925A (ja) 糖蛋白ｐに対するモノクローナル抗体
WO1989010133A1 (fr) Inhibiteurs de cellules a tiges
AU2002354096B2 (en) Cytotoxic protein and utilization thereof
AU673858B2 (en) Monoclonal antibody
CN113321730B (zh) Cldn18.2抗体及其应用
DE69925817T2 (de) Rekombinante onconase und fusionsproteine davon
EP0668923B1 (fr) Anticorps monoclonal
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载